bone mineral density in hiv-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in san francisco骨矿物质密度暴露前预防艾滋病毒阴性男性参与替诺福韦在旧金山随机临床试验.pdfVIP

Bone Mineral Density in HIV-Negative Men Participating in a Tenofovir Pre-Exposure Prophylaxis Randomized Clinical Trial in San Francisco 1,2 2 3 1 2 Albert Y. Liu *, Eric Vittinghoff , Deborah E. Sellmeyer , Risha Irvin , Kathleen Mulligan , Kenneth 4 5 2,6 7 7 7 Mayer , Melanie Thompson , Robert Grant , Sonal Pathak , Brandon O’Hara , Roman Gvetadze , Kata 8 8 1,2 Chillag , Lisa Grohskopf , Susan P. Buchbinder 1 San Francisco Department of Public Health, San Francisco, California, United States of America, 2 University of California San Francisco, San Francisco, California, United States of America, 3 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, 4 Fenway Health, Boston, Massachusetts, United States of America, 5 AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States of America, 6 Gladstone Institutes, San Francisco, California, United States of America, 7 Northrop Grumman, Atlanta, Georgia, United States of America, 8 Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America Abstract Background: Pre-exposure prophylaxis (PrEP) trials are evaluating regimens containing tenofovir-disoproxil fumarate (TDF) for HIV prevention. We determined the baseline prevalence of low bone mineral density (BMD) and the effect of TDF on BMD in men who have sex with men (MSM) in a PrEP trial in San Francisco. Methods/Findings: We evaluated 1) the prevalence